Indexed keywords
11BETA HYDROXYSTEROID DEHYDROGENASE 2;
ALDOSTERONE;
ANDROGEN RECEPTOR;
CORTICOSTERONE;
CYTOKINE;
HYDROCORTISONE;
MIFEPRISTONE;
MINERALOCORTICOID RECEPTOR;
OSTEOPONTIN;
PROGESTERONE;
PROGESTERONE RECEPTOR;
SPIRONOLACTONE;
MITOGEN ACTIVATED PROTEIN KINASE P38;
BLOOD VESSEL INJURY;
EDITORIAL;
HORMONE ACTION;
HUMAN;
HYPERPLASIA;
NEOINTIMA;
NONHUMAN;
PRIORITY JOURNAL;
PROTEIN EXPRESSION;
PROTEIN FAMILY;
SMOOTH MUSCLE FIBER;
VASCULAR FIBROSIS;
VASCULAR SMOOTH MUSCLE;
ANIMAL;
BIOSYNTHESIS;
DRUG EFFECT;
METABOLISM;
NOTE;
SIGNAL TRANSDUCTION;
ALDOSTERONE;
ANIMALS;
MAP KINASE SIGNALING SYSTEM;
MUSCLE, SMOOTH, VASCULAR;
MYOCYTES, SMOOTH MUSCLE;
OSTEOPONTIN;
P38 MITOGEN-ACTIVATED PROTEIN KINASES;
RECEPTORS, MINERALOCORTICOID;
1
84878246840
Aldosterone-induced osteopontin expression in vascular smooth muscle cells involves MR, ERK, and p38 MAPK
doi: 10.1007/s12020-012-9675-2
G.-X. Fu, C.-C. Xu, Y. Zhong, D.-L. Zhu, P.-J. Gao, Aldosterone-induced osteopontin expression in vascular smooth muscle cells involves MR, ERK, and p38 MAPK. Endocrine (2012). doi: 10.1007/s12020-012-9675-2
(2012)
Endocrine
Fu, G.-X.1
Xu, C.-C.2
Zhong, Y.3
Zhu, D.-L.4
Gao, P.-J.5
2
79955447217
Mineralocorticoid receptors: Evolutionary and pathophysiological considerations
10.1210/en.2010-1444
K.S. Kasssahn, M.A. Ragan, J.W. Funder, Mineralocorticoid receptors: evolutionary and pathophysiological considerations. Endocrinology 152, 1883-1890 (2011)
(2011)
Endocrinology , vol.152
, pp. 1883-1890
Kasssahn, K.S.1
Ragan, M.A.2
Funder, J.W.3
3
0023743171
Mineralocorticoid action - Target tissue-specificity is enzyme, not receptor, mediated
2845584 10.1126/science.2845584 1:CAS:528:DyaL1cXmt1akuro%3D
J.W. Funder, P.T. Pearce, R. Smith, A.I. Smith, Mineralocorticoid action - target tissue-specificity is enzyme, not receptor, mediated. Science 242, 583-585 (1988)
(1988)
Science , vol.242
, pp. 583-585
Funder, J.W.1
Pearce, P.T.2
Smith, R.3
Smith, A.I.4
4
0030444810
Exclusion of corticosterone from epithelial mineralocorticoid receptors is insufficient for selectivity of aldosterone action: In vivo binding studies
8940344 10.1210/en.137.12.5264 1:CAS:528:DyaK28Xnt1Ghurs%3D
J.W. Funder, K. Myles, Exclusion of corticosterone from epithelial mineralocorticoid receptors is insufficient for selectivity of aldosterone action: in vivo binding studies. Endocrinology 137, 5264-5268 (1996)
(1996)
Endocrinology , vol.137
, pp. 5264-5268
Funder, J.W.1
Myles, K.2
5
73349119698
Glucocorticoids activate cardiac mineralocorticoid receptors during experimental myocardial infarction
19841288 10.1161/HYPERTENSIONAHA.109.136242 1:CAS:528:DC%2BD1MXhtl2qurrO
A.S. Mihailidou, T.Y.L. Le, M. Mardini, J.W. Funder, Glucocorticoids activate cardiac mineralocorticoid receptors during experimental myocardial infarction. Hypertension 54, 1306-1312 (2009)
(2009)
Hypertension , vol.54
, pp. 1306-1312
Mihailidou, A.S.1
Le, T.Y.L.2
Mardini, M.3
Funder, J.W.4
6
33751549628
The role of the glucocorticoid receptor in mineralocorticoid/salt mediated cardiac fibrosis
16990342 10.1210/en.2006-0658 1:CAS:528:DC%2BD28Xht1yqtr3I
A.J. Rickard, J.W. Funder, P.J. Fuller, M.J. Young, The role of the glucocorticoid receptor in mineralocorticoid/salt mediated cardiac fibrosis. Endocrinology 147, 5901-5906 (2006)
(2006)
Endocrinology , vol.147
, pp. 5901-5906
Rickard, A.J.1
Funder, J.W.2
Fuller, P.J.3
Young, M.J.4
7
0033517302
The effect of spironolactone on morbidity and mortality in patients with severe heart failure
10471456 10.1056/NEJM199909023411001 1:CAS:528:DyaK1MXmtVyrurk%3D
B. Pitt, F. Zannad, W.J. Remme, R. Cody, A. Castaigne, A. Perez, J. Palensky, J. Wittes, The effect of spironolactone on morbidity and mortality in patients with severe heart failure. New Engl. J. Med. 341, 709-717 (1999)
(1999)
New Engl. J. Med. , vol.341
, pp. 709-717
Pitt, B.1
Zannad, F.2
Remme, W.J.3
Cody, R.4
Castaigne, A.5
Perez, A.6
Palensky, J.7
Wittes, J.8
